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OBJECTIVES We sought to evaluate B-type natriuretic peptide (BNP), alone and in comparison to cardiac
troponin I (cTnI) and high-sensitivity C-reactive protein (hs-CRP), for risk assessment at
initial presentation with ST-segment elevation myocardial infarction (STEMI).
BACKGROUND Elevated levels of BNP drawn two to four days after acute myocardial infarction are associated
with higher mortality. Sparse data are available on its use at first presentation with STEMI.
METHODS We obtained samples from 438 patients presenting within 6 h of STEMI enrolled in the
Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or Without Glycopro-
tein IIb/IIIa Inhibitor as Reperfusion Strategy in ST-Segment Elevation Myocardial
Infarction (ENTIRE)–Thrombolysis In Myocardial Infarction (TIMI)-23 trial. Outcomes
were assessed through 30 days.
RESULTS Median BNP was higher in patients who died (89 pg/ml, 25th to 75th percentile: 40 to 192),
compared with survivors (15 pg/ml, 25th to 75th percentile: 8.8 to 32, p  0.0001). Patients
with BNP80 pg/ml were at significantly higher risk of death (17.4% vs. 1.8%, p 0.0001).
Cardiac troponin established a gradient of mortality between the highest and lowest quartile
(7.9% vs. 0%, p  0.007). C-reactive protein was not associated with outcome. After
adjustment for cTnI, hs-CRP, and major clinical predictors, including age, heart failure,
anterior myocardial infarction location, heart rate, and blood pressure, a BNP level 80
pg/ml was associated with a seven-fold higher mortality risk (odds ratio 7.2, 95% confidence
interval 2.1 to 24.5, p  0.001). Patients with BNP 80 pg/ml were also more likely to have
impaired coronary flow (p  0.049) and incomplete resolution of ST-segment elevation (p 
0.05).
CONCLUSIONS Increased concentrations of BNP at initial presentation of patients with STEMI are
associated with impaired reperfusion after fibrinolysis and higher short-term risk of mortality.
These data support the value of combining markers of hemodynamic stress with traditional
approaches to risk assessment in acute myocardial infarction. (J Am Coll Cardiol 2004;44:
335–9) © 2004 by the American College of Cardiology Foundationv
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y-type natriuretic peptide (BNP) is released from the
ardiac ventricles in response to increased wall stress (1). It
as emerged as an aid to diagnosing congestive heart failure
CHF) (2) and has subsequently been studied in the setting
f acute coronary syndromes, where the plasma concentra-
ion rises rapidly over 24 h after ST-segment elevation
yocardial infarction (STEMI) (3–5). When measured two
o seven days after infarction, elevated levels of BNP
dentify patients with lower survival (6–9). Because of the
ime-dependent rise in BNP, the value of very early deter-
inations is less clear, and there are sparse data addressing
he prognostic implications of BNP drawn at the time of
resentation with STEMI (4). Moreover, the prognostic
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Manuscript received February 6, 2004; revised manuscript received March 27,i004, accepted April 6, 2004.alue of BNP relative to other biomarkers has not been
ssessed in this setting.
We thus evaluated the prognostic performance and clin-
cal correlates of BNP, assessed at the time of presentation,
long with cardiac troponin I (cTnI) and high-sensitivity
-reactive protein (hs-CRP) among patients with STEMI
n the Enoxaparin Tenecteplase-Tissue-Type Plasminogen
ctivator With or Without Glycoprotein IIb/IIIa Inhibitor
s Reperfusion Strategy in ST-Segment Elevation Myocar-
ial Infarction (ENTIRE)–Thrombolysis In Myocardial
nfarction (TIMI)-23 trial.
ETHODS
tudy population. The ENTIRE–TIMI-23 trial random-
zed 483 patients with STEMI to either full-dose tenect-
plase (TNK)–tissue-type plasminogen activator (tPA) or
alf-dose TNK-tPA plus abciximab and to either unfrac-
ionated heparin or enoxaparin (10). Patients age 21 to 75
ears presenting within 6 h were eligible. Exclusion criteria
ncluded shock, pulmonary edema requiring intubation, and
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BNP at Presentation in STEMI July 21, 2004:335–9reatinine clearance30 ml/min. The protocol and biomar-
er substudy were approved by the institutional review
oard at each institution, and all patients provided written,
nformed consent.
rocedures. Angiography performed 55 to 75 min after
eperfusion therapy was interpreted by the TIMI Angiographic
ore Laboratory in Boston. Myocardial tissue-level reperfu-
ion was categorized by the TIMI myocardial perfusion grade.
T-segment resolution was assessed using predefined criteria
t 180 min after fibrinolysis (11). Blood samples were obtained
efore fibrinolysis for analysis of cardiac biomarkers. Patients
ere followed through 30 days (10).
iomarker testing. B-type natriuretic peptide was mea-
ured in EDTA-anticoagulated plasma using the ADVIA
entaur BNP assay (Bayer, Tarrytown, New York). This
ssay has a minimal detectable concentration of 2.0 pg/ml
nd a total imprecision of 4.7% and 2.8% at 29 pg/ml and
10 pg/ml, respectively. The assay is calibrated to have the
ame cut-point for diagnosis of CHF as an existing method
2). Troponin I was measured using the ACS:180 (Bayer)
ith a decision limit of 0.1 ng/ml (12). High-sensitivity
esting for CRP was performed using an immunonephelo-
etric assay (Dade-Behring, Newark, Delaware). The de-
ision limit (15 mg/l) was prespecified (13).
tatistical analysis. The plasma levels of BNP were de-
cribed by the median (interquartile range). The concentration
f BNP was also categorized into quartiles and dichotomized
sing a prespecified decision limit (80 pg/ml) (14,15). An
xploratory evaluation of additional cut-points was performed
sing receiver-operating characteristics (ROC). The baseline
haracteristics of patients with and without elevated BNP were
ompared using the Wilcoxon rank-sum test for continuous
ariables and the chi-square test for categorical variables. The
ssociation between each biomarker and clinical outcomes was
valuated using the chi-square or Fisher exact test for dichot-
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
cTnI  cardiac troponin I
ENTIRE–TIMI-23  Enoxaparin Tenecteplase-Tissue-
Type Plasminogen Activator
With or Without Glycoprotein
IIb/IIIa Inhibitor as Reperfusion
Strategy in ST-Segment Elevation
Myocardial Infarction (ENTIRE)–
Thrombolysis In Myocardial
Infarction (TIMI)-23 trial
hs-CRP  high-sensitivity C-reactive
protein
MI  myocardial infarction
ROC  receiver-operating characteristics
STEMI  ST-segment elevation myocardial
infarction
TNK-tPA  tenecteplase–tissue-type
plasminogen activatormized comparisons and the chi-square test for trend across puartiles. Multivariate analyses of the association between
NP and outcomes were performed using logistic regression to
djust for the other biomarkers and for major clinical predictors
f mortality (age, anterior myocardial infarction [MI] location,
ime from symptom onset, heart rate, blood pressure, and
HF at presentation), as captured by the TIMI risk score for
TEMI. All analyses were performed using STATA v7-
ntercooled (STATA Corp., College Station, Texas).
ESULTS
he BNP results were available for 438 patients (91%). The
edian concentration of BNP at presentation was 15.6
g/ml (25th to 75th percentile: 9.1 to 32.6). Patients with
levated levels (80 pg/ml) were older and more likely to
ave a history of hypertension, angina, and CHF (Table 1).
onsistent with the greater prevalence of angina and CHF,
hey were also more likely to be receiving beta-blockers and
ngiotensin-converting enzyme inhibitors at presentation.
he proportion of patients with elevated BNP did not differ
etween men and women. The median time from symptom
nset was longer in patients with elevated BNP.
rognosis and BNP. The baseline concentration of BNP
as significantly higher in the 15 patients who died by 30
ays (89 pg/ml, 25th to 75th percentile: 40 to 192),
ompared with the 423 survivors (15 pg/ml, 25th to 75th
ercentile: 8.8 to 32, p  0.0001). The relationships
etween the baseline concentration of BNP (quartiles) and
linical outcomes are detailed in Table 2. Patients with BNP
n the highest quartile had an 11-fold higher risk of death
ompared to quartiles 1 to 3 (p  0.0001). When treated
ichotomously, BNP 80 pg/ml was associated with a
ignificantly higher risk of death through 30 days (p 
.0001) (Figs. 1 and 2). A trend toward more frequent new
r worsening CHF was also apparent among those with
NP 80 pg/ml (8.7% vs. 3.3%, p  0.09), with a
onsequently increased risk of death or CHF (23.9% vs. 5.1,
 0.0001).
In addition to evaluating the prespecified decision limit,
e performed an exploratory analysis of alternative cut-
oints. The ROC analysis indicated an optimal cut-point in
his data set of 80 pg/ml (Fig. 3). Using a decision limit
f 40 pg/ml, an elevated BNP was associated with a
10-fold higher risk of death (13.5% vs. 0.86%, p 
.0001) and a nearly five-fold higher risk of death/CHF
19.1% vs. 4.0%, p  0.0001). Notably, as a single predictor
or mortality, BNP performed very well (c statistic  0.81).
linical predictors and BNP and other biomarkers. Com-
ared with cTnI and hs-CRP, BNP was a substantially
ore robust marker of 30-day mortality (Fig. 1). C-reactive
rotein was not associated with mortality or recurrent MI in
his study. Patients with cTnI in the highest quartile were at
ncreased risk of death (Table 2). However, cTnI did not
ffer prognostic information independent of BNP (p  0.9,
djusted for BNP). In contrast, BNP maintained an inde-
endent contribution to risk assessment. Among patients
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July 21, 2004:335–9 BNP at Presentation in STEMIith positive cTnI results, those with BNP80 pg/ml were
t significantly higher risk of death at 30 days (p  0.0001)
Fig. 4). In addition, although few patients with negative
nitial cTnI results had elevated BNP, a trend toward higher
ortality was also evident among this group (p  0.081).
Moreover, assessed using logistic regression, BNP re-
ained independently associated with mortality (odds ratio
OR] 7.2, 95% confidence interval [CI] 2.1 to 24.5, p 
.001) after adjustment for cTnI and hs-CRP (evaluated as
ichotomous and continuous variables), as well as major
linical predictors of mortality (age, anterior MI location,
ime from symptom onset to fibrinolysis, heart rate, blood
ressure, and CHF at presentation). This independent risk
elationship with BNP was unaltered (OR 8.2, 95% CI 2.3
o 28.4, p  0.001) when the population was restricted to
Table 1. Univariate Associations With Elevate
BNP <
(n 
Demographics
Age (yrs) 57 (50
Female (%) 17
Risk factors
Hypertension (%) 24
Smoking (%) 54
Diabetes (%) 13
Dyslipidemia (%) 30
Previous angina (%) 28
Previous CHF (%) 0
Presenting characteristics
Anterior MI (%) 35
Heart rate (beats/min) 70 (60
Systolic BP (mm Hg) 136 (12
Time from symptom onset (h) 2.8 (2.
Previous medications
Aspirin (%) 14
Beta-blocker (%) 15
ACE inhibitor (%) 10
Antihyperlipidemic agent (%) 13
Data are presented as a percentage for dichotomous variables
ACE  angiotensin-converting enzyme; BNP  B-type n
failure; MI  myocardial infarction.
Table 2. Association Between Biomarkers and
Q1 Q
BNP
Concentration (pg/ml) 9 9
Death (%) 1.8
Re-infarction (%) 5.5
CHF (%) 2.7
cTnI
Concentration (ng/ml) 0.08 0.08
Death (%) 0
Re-infarction (%) 2.7
CHF (%) 3.5
hs-CRP
Concentration (mg/l) 1.1 1.1
Death (%) 4.4
Re-infarction (%) 4.4
CHF (%) 3.5
BNP  B-type natriuretic peptide; CHF  congestive hea
C-reactive protein; Q  quartile.hose with no history of CHF. The prognostic association
etween BNP and mortality was even stronger using a
ut-point of 40 pg/ml (OR 15.9, 95% CI 3.1 to 81, p 
.001; likelihood ratio test vs. 80 pg/ml, p  0.02).
ngiographic and electrocardiographic observations. El-
vated BNP at presentation was associated with evidence of
ubsequent impaired epicardial and myocardial reperfusion.
pecifically, patients with BNP80 pg/ml were more likely to
ave incomplete reperfusion of the infarct-related artery (Table
). In addition, elevated BNP was associated with incomplete
70%) resolution of ST-segment elevation, an indicator of
mpaired myocardial tissue-level reperfusion (95.8% vs. 79.2%,
 0.05) (Table 3) (11). The baseline concentration of BNP
as not a surrogate for extent of necrosis (Spearman’s rho 
0.065 for creatine kinase-MB fraction, p  0.19).
vels of BNP
/ml BNP >80 pg/ml
(n  46) p Value
67 (59, 70) 0.0001
21.7 0.5
41.3 0.016
39.1 0.5
13.0 0.9
37.0 0.3
47.8 0.007
6.5 0.0001
32.6 0.7
80 (65, 91) 0.008
0) 146 (133, 160) 0.003
) 3.6 (2.6, 4.8) 0.0001
40.0 0.0001
43.5 0.0001
34.8 0.0001
23.9 0.06
edian value (25th, 75th percentile) for continuous variables.
etic peptide; BP  blood pressure; CHF  congestive heart
ical Outcomes
Q3 Q4 p Value
16–32 32
0.9 11.1 0.0001
3.6 3.7 0.8
5.5 5.5 0.4
0.24–0.79 0.79
2.7 7.9 0.007
4.5 2.6 0.7
4.5 6.1 0.6
2.8–6.0 6.0
1.8 3.3 0.4
2.7 3.6 0.9
3.6 6.3 0.7
re; cTnI  cardiac troponin I; hs-CRP  high-sensitivityd Le
80 pg
390)
, 65)
.4
.7
.6
.5
.1
.6
.3
.7
, 80)
0, 15
0, 3.8
.8
.6
.2
.5
and m
atriurClin
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–15
0
2.8
1.8
–0.23
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4.5
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BNP at Presentation in STEMI July 21, 2004:335–9ISCUSSION
n this study of concurrent assessment of BNP, cTnI, and
s-CRP at the time of presentation with STEMI, we found
hat BNP was a robust and independent indicator of
ortality risk, with risk assessment performance superior to
TnI or hs-CRP. Even when assessed early after symptom
nset, BNP maintained the strong prognostic relationship
vident in previous studies with later sample acquisition (1).
linical application of biomarkers in STEMI. Cardiac
iomarkers provide prognostic information that is incre-
ental to clinical predictors in patients with STEMI.
atients with elevated cTnT at the time of presentation
ave two- to three-fold higher mortality risk at 30 days,
ndependent of the time from symptom onset (16). Sparse
ata exist on the prognostic importance of hs-CRP in
TEMI. In one study, patients with elevated CRP were
ore likely to suffer complications of acute MI (myocardial
upture, ventricular aneurysm, and death by one year) (17).
he contrasting absence of a relationship between hs-CRP
nd outcome in the ENTIRE–TIMI-23 trial may relate
oth to the very early sample acquisition and the assessment
f short- rather than long-term outcomes.
Including our present analysis, BNP has been evaluated
n at least seven studies of patients with STEMI (1,3,4,
–8). Together, these studies provide consistent evidence
igure 1. Relationship between elevated biomarkers and mortality at 30
ays. Positive results (solid bars) were defined as B-type natriuretic peptide
BNP) 80 pg/ml, cardiac troponin 0.1 ng/ml, and high sensitivity
-reactive protein (CRP) 15 mg/l (negative results  open bars).
igure 2. Probability of death through 30 days stratified by B-type
(atriuretic peptide (BNP).or the additive prognostic value of BNP. Although BNP
evels are correlated with age, gender, intracardiac pressures,
jection fraction, and renal function, BNP provides prog-
ostic information that is independent of these variables.
oreover, whether measured at presentation, as in the
resent report, or later during recovery, BNP is one of the
ost robust indicators of mortality risk. This strong prog-
ostic association in STEMI parallels that among patients
ith non–ST-segment elevation acute coronary syndromes
15). An important and, as yet, unanswered question is
hether biomarkers, such as BNP, evaluated in STEMI
hould be used to select specific therapies.
Mechanistic information provided in this and other
tudies (18) points toward hypotheses regarding interven-
ions that may ameliorate this risk. We have shown that an
levated BNP level before fibrinolysis is associated with a
ower likelihood of successful epicardial and myocardial
eperfusion. Although not directly addressed in this study,
e may speculate that underlying left ventricular hypertro-
hy, unrecognized left ventricular dysfunction, and/or a
arge territory of infarct/ischemia may be contributing to the
ncreased concentration of BNP and are associated with
igure 3. The receiver-operator characteristic curve for B-type natriuretic
eptide at 10-pg/ml intervals for predicting death at 30 days.
igure 4. Association of B-type natriuretic peptide (BNP), in conjunction
ith cardiac troponin and high sensitivity C-reactive protein (CRP), with
ortality at 30 days. Positive results (solid bars) were defined as BNP80
g/ml, cardiac troponin 0.1 ng/ml, and high sensitivity CRP 15 mg/l
negative results  open bars).
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July 21, 2004:335–9 BNP at Presentation in STEMImpaired reperfusion and increased mortality. Therefore,
atients with elevated BNP may be particularly appropriate
andidates for primary angioplasty and for transfer when
resenting to hospitals without available catheterization
acilities. Others have shown that when measured sub-
cutely after MI, elevated BNP identifies patients at risk of
dverse left ventricular remodeling, chronic left ventricular
ysfunction, and CHF (1). In this setting, routine treat-
ent, even among patients without evident left ventricular
ysfunction or CHF, with afterload-reducing agents or
ovel agents that may improve infarct healing or ventricular
emodeling after MI, may be particularly beneficial.
tudy limitations. Limitations to this analysis should be
onsidered. First, given the relatively low mortality rate in
his study, it is possible that an association between hs-CRP
nd short-term mortality could not be detected. However,
he observations regarding the relative strength of the risk
elationships for BNP compared with cTnI and hs-CRP are
nlikely to be altered in a larger population. Second,
lthough this study provides interesting data on the associ-
tion of BNP with impaired reperfusion, it does not provide
irect insight into the underlying pathobiology. Third, the
revalence of pre-existing CHF among patients presenting
ith STEMI in the community is higher than that observed
n this trial. It is possible that the prognostic implications of
levated BNP in patients with chronic CHF presenting
ith STEMI differ from those of patients without chronic
HF. Also, the lower cut-point (40 pg/ml) may not be
ptimal in populations with a greater proportion of women
nd elderly. For these reasons, additional community-based
tudies with STEMI will be valuable.
onclusions. In patients with STEMI, elevated levels of
NP at initial presentation are associated with impaired
eperfusion after fibrinolysis and increased risk of short-
erm mortality. These data support the value of combining
arkers of hemodynamic stress, such as BNP, with estab-
able 3. Association Between Biomarkers, Coronary Flow, and
lectrocardiographic Abnormalities
Impaired
Flow
Poor
Myocardial
Perfusion
Failed
ST-Segment
Resolution
NP (%)
80 pg/ml 47.5 46.1 79.2
80 pg/ml 64.1 53.8 95.8
p Value 0.049 0.362 0.05
40 pg/ml 46.5 44.5 77.2
40 pg/ml 59.5 56.4 95.6
p Value 0.04 0.06 0.005
TnI (%)
0.1 ng/ml 43.3 46.9 72.8
0.1 ng/ml 51.3 47.5 83.2
p Value 0.157 0.923 0.072
s-CRP (%)
15 mg/l 48.6 47.3 79.6
15 mg/l 50.0 46.4 84.2
p Value 0.887 0.926 0.632
bbreviations as in Table 2.ished biomarkers of necrosis, for risk assessment at the time
f presentation with acute MI.
eprint requests and correspondence: Dr. David A. Morrow,
IMI Study Group/Cardiovascular Division, Brigham and Wom-
n’s Hospital, 75 Francis Street, Boston, Massachusetts 02115.
-mail: dmorrow@partners.org.
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